Pfizer announces results of ABRYSVO for RSV in immunocompromised adults
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Strong topline growth driven by solid performance across key brands.
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
India boasts the largest livestock population, with 536 million livestock and 851 million poultry
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Subscribe To Our Newsletter & Stay Updated